Core Viewpoint - Marubi Biological has officially started construction on a Class III medical device pilot base in Zhuhai, focusing on the research and industrialization of recombinant collagen protein in the medical beauty field, indicating a strategic shift from a cosmetics company to a biotechnology company [1][3]. Company Developments - The project aims to deepen research into recombinant collagen protein, expanding its application from cosmetic beauty to medical beauty, reflecting Marubi's ambition to enhance its competitive edge in the cosmetics industry and explore new revenue streams in the medical sector [1][3]. - Marubi has changed its name from "Marubi Co., Ltd." to "Marubi Biological" and has invested in medical biomaterials companies, signaling a commitment to this new direction [1][3]. Market Trends - The focus on recombinant collagen protein aligns with Marubi's historical emphasis on anti-aging products, particularly in eye care, and the growing popularity of this ingredient in the skincare market [3][4]. - The market for recombinant collagen protein is still in its early stages, presenting opportunities for early entrants like Marubi to capture market share [3][4]. Research and Development Strategy - Marubi plans to invest over 1 billion yuan in recombinant collagen protein research by 2032, with specific milestones including obtaining medical device registration by 2026 and advancing into serious medical applications by 2028 [4][5]. - Despite the ambitious R&D plans, Marubi's R&D expenses have not kept pace with revenue growth, leading to a decline in R&D expense ratios from 2.80% in 2023 to 2.48% in 2024 [5][9]. Financial Performance - Marubi's revenue has shown significant growth, surpassing 2.2 billion yuan in 2023, a 28.52% increase from the previous year, with projections indicating potential revenue exceeding 3 billion yuan by 2025 [7][9]. - The company has successfully adapted its marketing strategies, particularly through online channels and product focus, contributing to its revenue growth [7][8]. Competitive Landscape - Marubi faces challenges from increasing online marketing costs and rising sales expenses, which have impacted profitability, with net profit margins decreasing from 26.56% in 2020 to 11.52% in 2024 [9][10]. - The reliance on a single ingredient, recombinant collagen protein, poses risks, as market trends can shift rapidly, potentially affecting long-term sustainability [9][10].

Fixed Income - The bank wealth management market's existing scale reached 30.67 trillion yuan as of H1 2025, an increase of 0.72 trillion yuan compared to the end of 2024, surpassing the average change of -0.13 trillion yuan from H1 2021 to H1 2024 [2][7][8] - The average annualized yield of wealth management products weakened in H1 2025, with an average yield of 2.12%, down 0.53 percentage points from the entire year of 2024 [9][10] - The market is expected to stabilize above 30 trillion yuan in H2 2025, with a focus on long-term municipal investment bonds and capital bonds [10] New Consumption - Maternal and Infant Industry - The implementation of the childcare subsidy policy is expected to stimulate the maternal and infant industry, with the market size projected to reach 76,299 billion yuan in 2024 and 89,149 billion yuan by 2027 [12][13] - The birth population in China is expected to increase to 9.54 million in 2024, marking a rise of 520,000 from 2023, the first increase since 2017 [13] - The policy aims to alleviate family burdens and enhance birth rates, benefiting sectors such as dairy products, education and training, and infant care [13] New Consumption - Investment Opportunities - The high-end beauty sector is expected to grow faster than the mass market, with projected CAGR of 9.6% for skincare and 10.8% for makeup from 2023 to 2028 [14][15] - The ancient gold market shows strong growth potential, with a CAGR of 21.8% expected from 2023 to 2028 [15][16] - The current beverage market is seeing a rise in ready-to-drink products, with the market size for ready-to-drink beverages reaching 5,175 billion yuan in 2023, accounting for 36.3% of the beverage market [16][17] Medical Devices - Kaili Medical - Kaili Medical is positioned as a leader in ultrasound and endoscopy equipment, with new product launches expected to enhance market penetration [19][20] - The company has expanded its workforce significantly, preparing for a recovery in the medical device sector, with procurement activities showing signs of normalization [20][21] - Revenue forecasts for Kaili Medical indicate a growth trajectory, with expected revenues of 2.388 billion yuan in 2025, growing to 3.224 billion yuan by 2027 [21] Transportation - YTO Express - YTO Express reported a revenue of 5.53 billion yuan in June 2025, reflecting a year-on-year increase of 11.35%, with a business volume growth of 19.34% [23][24] - The express delivery market is experiencing structural growth, with YTO's business volume growth outpacing overall market growth [24][25] - The "anti-involution" policy is expected to improve profitability in the express delivery sector, with YTO's net profit per ticket projected to increase significantly [25][26]

Investment Rating - The report maintains a "Positive" investment rating, highlighting the favorable momentum in new consumption sectors, particularly in beauty care, gold, trendy toys, and freshly brewed tea drinks [4]. Core Insights - The new consumption landscape reflects the evolving consumer preferences of the younger generation, emphasizing the importance of understanding these narratives for capturing growth opportunities in new consumption companies [80]. Beauty Care Sector - The high-end beauty segment is expected to grow faster than the mass market, with projected CAGR for high-end skincare and makeup at 9.6% and 10.8% respectively from 2023 to 2028, compared to 8.2% and 6.7% for mass-market products [5][9]. - Domestic brands are gaining market share, with the national beauty market share reaching 50.4% in 2023, surpassing foreign brands [15][18]. Gold Jewelry Sector - The gold jewelry market in China is projected to grow from 820 billion yuan in 2023 to 1,140 billion yuan by 2028, with a CAGR of 6.8% [19]. - The ancient gold segment shows strong growth potential, with a CAGR of 21.8% expected from 2023 to 2028, despite a slowdown in growth rates [24][25]. Trendy Toys Sector - The trendy toy market in China reached 626 billion yuan in 2023, with a CAGR of 31.24% from 2019 to 2023, indicating rapid growth [40]. - The market concentration is increasing, with the top five companies' market share rising from 22.8% in 2019 to 26.4% in 2021 [46]. Freshly Brewed Tea Drinks Sector - The freshly brewed tea drink market in China was valued at 517.5 billion yuan in 2023, accounting for 36.3% of the beverage market, with expectations to reach 1,163.4 billion yuan by 2028 [67]. - The market for freshly brewed tea drinks is anticipated to maintain its position as the largest segment within the freshly brewed beverage category, with a projected CAGR of 17.3% from 2023 to 2028 [71][75].

Investment Rating - The industry rating is "Outperform the Market" [7] Core Insights - The report highlights the significant impact of the WAIC exhibition on AI and consumer opportunities, particularly in the tourism and education sectors [2][4] - The construction of the Yajiang Hydropower Station is expected to significantly boost tourism in Tibet, benefiting leading companies in the region [3][25] - The Hainan Free Trade Port is set to officially start operations on December 18, 2025, which will enhance the user base for duty-free shopping and improve performance in the sector [3][15][17] Summary by Sections 1. Duty-Free and Scenic Areas - The Yajiang Hydropower Station is expected to increase tourist traffic in Tibet, particularly in the Linzhi and Ali regions, which host several national scenic spots [3][22][25] - The Hainan Free Trade Port's upcoming closure will allow visa-free entry for citizens from 85 countries, significantly increasing the user base for duty-free shopping [15][17] 2. Medical Aesthetics - The medical aesthetics industry is experiencing a recovery, with a focus on refined operations and market share optimization among leading institutions [26] - New product releases from upstream manufacturers are anticipated to enhance market dynamics, with companies like JINBO and Sihuan Pharmaceutical being highlighted for their innovative offerings [26][29] 3. Beauty and Personal Care - The beauty and personal care sector is undergoing a transformation due to the "traffic tax" policy, which is expected to increase market concentration among leading brands [37][39] - The demand for mosquito repellent products is rising due to the spread of the Chikungunya virus, benefiting companies like Runben [38][39] 4. Trendy Toys - Recent policies focusing on consumer stimulation and industry regulation are expected to support the performance of compliant leading companies in the trendy toy sector [40] 5. Education - The report emphasizes the progress in AI+Education, with several companies launching AI education products that are expected to see significant revenue growth [4][50] - Notable companies in this space include DouShen Education and ShengTong Education, which are introducing innovative AI-driven educational platforms [44][50]

胶原蛋白赛道或将迎来竞争高峰期。 药企德展健康日前宣布，其重组Ⅲ型及XVII型人源化胶原蛋白已实现中试生产，并具备化妆品原料销 售能力。但在这项技术突破背后，横亘着医药级原料转化的巨大鸿沟——规模化生产线仍在建设中，真 正的产业化部署尚未完成。 事实上，在所有玩家头顶高悬的双重高压线并未松动：技术层面，医美级产品的规模化生产与质量控制 仍如绝壁矗立；准入层面，长达36个月的三类医疗器械审批周期与超千万元的单产品合规成本构筑着钢 铁闸门。 围绕重组胶原蛋白项目技术突破及申报节奏，21世纪经济报道以投资者身份致电德展健康。该公司工作 人员回复道："其技术路线与巨子生物等行业头部企业同属人源化胶原蛋白范畴，并无本质差别。当前 中试生产规模维持在500L水平，产品技术性能可满足护肤品、医美等商业化应用需求。" 但工作人员同时指出，由于尚未建立规模化量产能力，具体产业化路径仍需结合后续产能建设情况确 定。 德展健康产品结构显示，公司已布局重组胶原蛋白原料及其衍生产品体系。2024年，重组Ⅲ型人源化胶 原蛋白不仅实现原料销售，其创新的冻干海绵剂型产品也通过备案审批。 作为第三代胶原蛋白技术，该产品通过DNA重组技术构建三 ...

Core Viewpoint - The Hang Seng Healthcare Index (HSHCI) has shown positive performance, with significant increases in constituent stocks, indicating a favorable market environment for healthcare investments [3][4]. Group 1: Market Performance - As of July 28, 2025, the HSHCI rose by 0.64%, with notable gains from stocks such as MicroPort Medical (up 9.51%) and Eddy Health Holdings (up 3.93%) [3]. - The Hang Seng Healthcare ETF (513060) opened higher, increasing by 1.22% to a latest price of 0.66 yuan, and has accumulated a 0.92% rise over the past week [3]. - The ETF recorded a turnover of 0.79% during the trading session, with a transaction volume of 61.18 million yuan, and an average daily trading volume of 2.815 billion yuan over the past week, ranking first among comparable funds [3]. Group 2: Policy and Industry Outlook - The national procurement policy is expected to expand from pharmaceuticals to medical devices, potentially leading to performance reversals in high-value consumables and in vitro diagnostics sectors [4]. - The medical device sector is anticipated to benefit from a recovery in procurement activities this year, with expectations of an earnings turning point in the third quarter [4]. Group 3: ETF Performance Metrics - The latest size of the Hang Seng Healthcare ETF is 7.656 billion yuan, placing it in the top third among comparable funds [4]. - The ETF has seen a net value increase of 29.88% over the past two years, with a maximum monthly return of 28.34% since inception [4]. - The ETF's Sharpe ratio for the past year is 2.30, indicating strong risk-adjusted returns [4]. Group 4: Valuation and Tracking Accuracy - The HSHCI's latest price-to-earnings ratio (PE-TTM) is 31.72, which is below 84.29% of the historical data over the past three years, suggesting a low valuation [6]. - The ETF has the highest tracking accuracy among comparable funds, with a tracking error of 0.060% over the past year [6]. - The top ten weighted stocks in the HSHCI account for 60.54% of the index, including companies like BeiGene and WuXi Biologics [6].

Core Viewpoint - Huaxi Biological, a major player in the medical aesthetics industry, is facing significant turmoil due to allegations of financial fraud and internal disputes, raising uncertainties about its future performance and ability to recover its previous market stature [1][2]. Group 1: Allegations and Internal Conflicts - On July 25, a former employee, claiming to be a whistleblower, accused Huaxi Biological of financial fraud and plans to submit evidence to regulatory authorities [3]. - Huaxi Biological responded on July 26, denying the allegations and stating that the claims are fabricated and defamatory, leading to a police report against the accuser [3][4]. - The company has faced multiple internal complaints in recent years, including accusations of misappropriating shareholder interests and disputes over profit distribution among executives [4][5]. Group 2: Financial Performance - Huaxi Biological has experienced a decline in both revenue and net profit for two consecutive years, with Q1 2025 showing further decreases, reporting a net profit of 1.02 billion yuan [1][9]. - The company's revenue fell from 63.59 billion yuan in 2022 to 53.71 billion yuan in 2024, marking a year-on-year decline of 11.61% [9]. - The proportion of revenue from functional skincare products decreased from 61.83% in 2023 to 47.84% in 2024, while terminal business revenue grew significantly during the same period [9]. Group 3: Market Position and Valuation - At its peak in 2021, Huaxi Biological's market capitalization exceeded 150 billion yuan, but it has since plummeted to approximately 26 billion yuan, resulting in a loss of over 120 billion yuan in market value [1][11]. - The company's stock price as of July 25, 2025, was 53.83 yuan per share, reflecting the significant decline from its previous highs [11].

Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Viewpoints - The retail industry is experiencing a recovery, with significant growth in specific segments such as beauty and jewelry, driven by consumer sentiment and innovative business models [8][30] - The launch of the AI model by Yiwu Small Commodity City is expected to enhance operational efficiency and empower merchants, indicating a shift towards technology-driven business practices [25][26] Summary by Sections Retail Market Review - The retail industry index rose by 3.28% during the week of July 21-25, outperforming the Shanghai Composite Index by 1.61 percentage points [7][14] - The brand cosmetics sector saw the highest weekly increase of 5.94%, while the jewelry sector led the year-to-date performance with a 28.93% increase [17][20] Industry Dynamics - Yiwu Small Commodity City partnered with Alibaba to initiate the AI model testing, which is expected to transform traditional trade practices and enhance global trade linkages [25][26] - Over 30,000 merchants in Yiwu are utilizing AI tools, with deep users experiencing over 30% growth in orders, showcasing the impact of AI on operational efficiency and brand enhancement [26] Investment Recommendations - Focus on high-quality companies in sectors benefiting from emotional consumption themes, including: - Gold and jewelry brands with differentiated product offerings, such as Laopuhuang and Chaohongji [8][30] - Retail enterprises adapting to trends, like Yonghui Supermarket and Aiyingshi [8][30] - Domestic beauty brands with strong growth potential, including Maogeping and Pola [8][30] - Medical beauty product manufacturers with unique pipelines, such as Aimeike and Kedi-B [8][30] Company-Specific Insights - Laopuhuang reported a revenue increase of 167.5% and a net profit increase of 253.9% in FY2024, indicating strong brand expansion [32] - Chaohongji achieved a revenue growth of 25.4% in Q1 2025, driven by its focus on fashionable jewelry targeting younger consumers [40] - Maogeping's revenue grew by 34.6% in FY2024, reflecting its position as a leading domestic high-end beauty brand [32] - Pola's revenue increased by 21.0% in FY2024, supported by a robust product lineup [32]

Investment Rating - The report maintains a "Positive" outlook on the cosmetics and medical beauty industry, highlighting the strong performance of domestic brands amid stricter regulations [1]. Core Insights - The cosmetics and medical beauty sector outperformed the market, with the Shenwan Beauty Care Index rising by 5.4% from July 18 to July 25, 2025, surpassing the Shenwan A Index by 1.2 percentage points [5][6]. - Stricter advertising regulations are expected to benefit leading domestic brands, as new rules will increase operational barriers and allow market share to concentrate among top players [11]. - The report emphasizes the importance of new product launches as brands prepare for the competitive landscape in the second half of 2025 [11]. Summary by Sections Industry Performance - The Shenwan Cosmetics Index increased by 3.4%, outperforming the Shenwan A Index by 1.2 percentage points, while the Shenwan Personal Care Index rose by 7.7%, exceeding the Shenwan A Index by 5.5 percentage points [5][6]. Key Company Highlights - Lin Qingxuan, a high-end domestic skincare brand, saw revenue grow from 690 million yuan in 2022 to 1.21 billion yuan in 2024, with net profit turning from a loss of 6 million yuan to a profit of 187 million yuan [17]. - The company has a diverse product matrix with 188 SKUs, a robust supply chain with an annual production capacity of 40 million units, and a comprehensive OMO channel strategy [19]. Market Trends - The report notes a shift in the cosmetics market from quantity to quality, with e-commerce sales expected to account for 47% of total cosmetics sales by 2024, up from 22% in 2016 [13]. - The domestic market is witnessing a rise in local brands, with significant market share gains, particularly in the skincare segment [37]. Investment Recommendations - The report recommends several companies based on their market positioning and growth potential, including Up Beauty, Proya, and Marubi, while suggesting to pay attention to Shanghai Jahwa, Betaini, and Huaxi Biological [5].

Core Viewpoint - The article discusses serious allegations against Huaxi Biological, a leading player in the medical aesthetics industry, regarding financial misconduct and governance issues, which have led to significant market concerns and a drastic decline in the company's stock price and market value [1][4][12]. Company Response - Huaxi Biological quickly responded to the allegations, stating that the claims are fabricated and maliciously distort the facts, and they have reported the matter to law enforcement [2][6][8]. - The company emphasized that the whistleblower, Li, had a brief tenure and was previously involved in a financial misconduct case, which raises questions about the credibility of the allegations [10][11]. Market Impact - Following the allegations, Huaxi Biological's stock price fell to 53.83 CNY, a decrease of 1.73%, with a market capitalization of 25.9 billion CNY, reflecting a significant drop from its peak valuation of over 100 billion CNY [5][14]. - The company's market value has shrunk by over 80% from its peak, indicating a severe loss of investor confidence [14][15]. Financial Performance - Huaxi Biological's financial performance has deteriorated, with a reported revenue of 5.371 billion CNY in 2024, down 11.61% year-on-year, and a net profit of 174 million CNY, a staggering decline of 70.59% [18]. - The first quarter of 2025 showed continued declines in revenue and net profit, with year-on-year decreases of 20.77% and 58.13%, respectively [19]. Industry Context - The medical aesthetics industry is facing intense competition, with Huaxi Biological struggling against rivals like Juzhi Biological, which has seen significant growth and market capitalization [22][24]. - The article highlights a shift in consumer preferences towards product safety and efficacy, suggesting that companies with genuine technological advantages will prevail in the evolving market landscape [24].